Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PRGN-3007 by Precigen for Hematological Tumor: Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Hematological Tumor. According to GlobalData, Phase I...
PRGN-3007 by Precigen for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
PRGN-3007 by Precigen for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
PRGN-3007 by Precigen for Solid Tumor: Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
PRGN-3007 by Precigen for Mantle Cell Lymphoma: Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase...
PRGN-3007 by Precigen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
PRGN-3007 by Precigen for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
PRGN-3007 by Precigen for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
PRGN-3007 is under clinical development by Precigen and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to...